Edwards Lifesciences Gross Margin 2010-2022 | EW

Current and historical gross margin for Edwards Lifesciences (EW) over the last 10 years. The current gross profit margin for Edwards Lifesciences as of December 31, 2022 is %.
Edwards Lifesciences Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2022-12-31 $5.38B $4.30B 79.93%
2022-09-30 $5.36B $4.23B 78.90%
2022-06-30 $5.36B $4.17B 77.78%
2022-03-31 $5.36B $4.10B 76.57%
2021-12-31 $5.23B $3.98B 76.11%
2021-09-30 $5.10B $3.86B 75.72%
2021-06-30 $4.93B $3.72B 75.52%
2021-03-31 $4.48B $3.37B 75.20%
2020-12-31 $4.39B $3.31B 75.36%
2020-09-30 $4.37B $3.30B 75.51%
2020-06-30 $4.32B $3.24B 74.99%
2020-03-31 $4.48B $3.34B 74.42%
2019-12-31 $4.35B $3.23B 74.38%
2019-09-30 $4.15B $3.09B 74.40%
2019-06-30 $3.97B $2.97B 74.88%
2019-03-31 $3.82B $2.88B 75.46%
2018-12-31 $3.72B $2.78B 74.76%
2018-09-30 $3.64B $2.69B 74.11%
2018-06-30 $3.55B $2.62B 73.80%
2018-03-31 $3.45B $2.55B 74.04%
2017-12-31 $3.44B $2.56B 74.48%
2017-09-30 $3.32B $2.46B 74.22%
2017-06-30 $3.23B $2.39B 73.96%
2017-03-31 $3.15B $2.32B 73.56%
2016-12-31 $2.96B $2.17B 73.10%
2016-09-30 $2.87B $2.11B 73.52%
2016-06-30 $2.74B $2.04B 74.30%
2016-03-31 $2.60B $1.94B 74.55%
2015-12-31 $2.49B $1.88B 75.22%
2015-09-30 $2.44B $1.84B 75.34%
2015-06-30 $2.43B $1.81B 74.38%
2015-03-31 $2.39B $1.78B 74.27%
2014-12-31 $2.32B $1.70B 73.13%
2014-09-30 $2.24B $1.63B 72.86%
2014-06-30 $2.13B $1.56B 73.27%
2014-03-31 $2.07B $1.53B 73.88%
2013-12-31 $2.05B $1.53B 74.73%
2013-09-30 $2.02B $1.53B 75.50%
2013-06-30 $1.97B $1.49B 75.76%
2013-03-31 $1.94B $1.45B 74.96%
2012-12-31 $1.90B $1.41B 74.14%
2012-09-30 $1.82B $1.33B 73.17%
2012-06-30 $1.78B $1.28B 71.86%
2012-03-31 $1.73B $1.23B 71.15%
2011-12-31 $1.68B $1.19B 70.82%
2011-09-30 $1.64B $1.16B 70.51%
2011-06-30 $1.58B $1.12B 71.21%
2011-03-31 $1.51B $1.09B 71.81%
2010-12-31 $1.45B $1.04B 71.80%
2010-09-30 $1.40B $1.01B 71.68%
2010-06-30 $1.38B $0.98B 70.99%
2010-03-31 $1.35B $0.95B 70.22%
2009-12-31 $1.32B $0.92B 69.77%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $50.772B $5.382B
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $230.517B 25.29
Alcon (ALC) Switzerland $37.369B 32.17
STERIS (STE) Ireland $21.864B 27.21
Teleflex (TFX) United States $12.124B 19.67
Fresenius Medical Care AG KGaA (FMS) Germany $11.123B 11.16
Penumbra (PEN) United States $9.913B 2372.91
Globus Medical (GMED) United States $7.950B 40.42
Glaukos (GKOS) United States $2.458B 0.00
Integer Holdings (ITGR) United States $2.435B 19.55
AVANOS MEDICAL, INC (AVNS) United States $1.469B 20.92
Nevro (NVRO) United States $1.410B 0.00
Paragon 28 (FNA) United States $1.346B 0.00
Artivion (AORT) United States $0.566B 0.00